Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Okyo Pharma Limited ADR (OKYO)

Okyo Pharma Limited ADR (OKYO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall Street - NYSE Full View
S&P Futures Climb Ahead of Key U.S. PPI Data, ECB Decision in Focus Barchart - Thu Sep 14, 2023

September S&P 500 futures (ESU23) are trending up +0.29% this morning after three major U.S. benchmark indices ended the regular session mixed as investors digested the latest U.S. inflation report while...

ESU23 : 4,491.72s (-0.32%)
MRNA : 39.39 (-0.43%)
JBHT : 170.23 (+1.27%)
F : 9.88 (+1.44%)
AAL : 16.88 (+1.44%)
ADBE : 447.17 (+2.24%)
CPRT : 58.22 (-0.39%)
LEN : 138.08 (-0.23%)
ROO.L.EB : 142.850 (+2.55%)
SMTC : 63.55 (-0.05%)
PCT : 10.85 (+4.63%)
MET : 81.36 (+1.56%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030 FinancialNewsMedia - Fri Sep 8, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.0600 (-2.75%)
ALC : 84.76 (+0.69%)
BLCO : 18.00 (+0.28%)
JNJ : 144.47 (+0.62%)
RHHBY : 34.5000 (+0.76%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030 PR Newswire - Fri Sep 8, 2023

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.0600 (-2.75%)
ALC : 84.76 (+0.69%)
BLCO : 18.00 (+0.28%)
JNJ : 144.47 (+0.62%)
RHHBY : 34.5000 (+0.76%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments FinancialNewsMedia - Tue May 2, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

OKYO : 1.0600 (-2.75%)
OKYO.LN : 1.400 (-24.32%)
NVS : 97.11 (+0.35%)
ALDX : 4.88 (+0.41%)
OCUL : 8.50 (+0.59%)
EYPT : 7.10 (-0.28%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments PR Newswire - Tue May 2, 2023

/PRNewswire/ -- The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the...

OKYO : 1.0600 (-2.75%)
NVS : 97.11 (+0.35%)
ALDX : 4.88 (+0.41%)
OCUL : 8.50 (+0.59%)
EYPT : 7.10 (-0.28%)
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm Business Wire - Tue Aug 30, 2022

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022...

OKYO : 1.0600 (-2.75%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Thu Jun 9, 2022

LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing...

OKYO : 1.0600 (-2.75%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Fri May 20, 2022

LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and...

OKYO : 1.0600 (-2.75%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing Globe Newswire - Thu May 19, 2022

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused...

OKYO : 1.0600 (-2.75%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing Globe Newswire - Wed May 18, 2022

LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and...

OKYO : 1.0600 (-2.75%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)

Barchart Exclusives

Why This Solar Stock Is a Tariff Winner to Buy for 2025 Barchart - 9 minutes ago
First Solar could be the "sole" beneficiary of new U.S. anti-dumping tariffs on countries like Vietnam and Malaysia. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot